<div id="readability-page-1"><ul><li>FDA Approves Novo Nordisk's Wegovy Pill: A Game Changer for 2026</li></ul><p>Eli Lilly and Company, Pfizer,  and Axsome Therapeutics are the three Pharmaceutical stocks to watch today, according to MarketBeat's stock screener tool. Pharmaceutical stocks are shares of publicly traded companies that research, develop, manufacture, and sell prescription drugs, vaccines, and related therapies, and they span large diversified drugmakers to smaller biotech firms. Investors buy them for exposure to potential high returns from successful clinical trials and approvals, but must accept substantial regulatory, clinical trial, patent and pricing risks that can cause pronounced volatility. These companies had the highest dollar trading volume of any Pharmaceutical stocks within the last several days.</p><div><p><span></span><span>Get <strong>Eli Lilly and Company</strong> alerts:</span></p></div><h2>Eli Lilly and Company (LLY)</h2><p>Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.</p><ul><li>Why Wall Street Gave Up on Pfizer—and Why That May Be a Mistake</li></ul><p>Read Our Latest Research Report on LLY</p><h2>Pfizer (PFE)</h2><p>Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.</p><ul><li>Eli Lilly’s New Drug Data Sets Up a High-Stakes 2026</li></ul><p>Read Our Latest Research Report on PFE</p><h2>Axsome Therapeutics (AXSM)</h2><p>Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.</p><p>Read Our Latest Research Report on AXSM</p><h2>See Also</h2><ul><li>MarketBeat's Top Five Stocks to Own in December 2025</li><li>Microsoft Is Lagging the Market—But Its Moat May Matter More in 2026</li><li>The Kroger Catalyst: $2 Billion Reasons to Buy</li><li>Why Wall Street Gave Up on Pfizer—and Why That May Be a Mistake</li><li>Gold, Silver, and Copper Are Surging—Here Are 3 Smart Ways to Play It</li><li>What to Expect From Amazon in the 4 Weeks Before Earnings</li></ul><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Eli Lilly and Company Right Now?</h2><p>Before you consider Eli Lilly and Company, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.</p><p>While Eli Lilly and Company currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

AXSM

<p>Eli Lilly, Pfizer, and Axsome Therapeutics are highlighted as key pharmaceutical stocks to watch, according to MarketBeat. These companies have shown high trading volumes recently, indicating investor interest. Eli Lilly focuses on diabetes and obesity treatments, Pfizer offers a range of medicines and vaccines, and Axsome develops therapies for CNS disorders. The pharmaceutical sector presents potential high returns but also carries significant risks due to regulatory and clinical challenges. Investors are advised to consider these stocks carefully amid market volatility.</p>

- FDA has approved Novo Nordisk's Wegovy pill, a noteworthy development for the pharmaceutical industry in 2026.  
- Eli Lilly & Company, Pfizer, and Axsome Therapeutics are highlighted as key pharmaceutical stocks with significant trading volume recently.  
- These companies are engaged in developing therapies for various medical conditions, which carries both high potential returns and substantial risks for investors.

Pharmaceutical Stocks To Follow Now - December 31st